monoisoamyl-2,3-dimercaptosuccinate has been researched along with Cell Transformation, Neoplastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Flora, SJS; Sathua, K; Srivastava, S | 1 |
| Acharya, S; Basu, AK; Bhattacharya, D; Chatterjee, S; Chaudhuri, S; Dasgupta, S; Flora, SJ; Kumar, P; Singh, MK | 1 |
2 other study(ies) available for monoisoamyl-2,3-dimercaptosuccinate and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
MiADMSA ameliorate arsenic induced urinary bladder carcinogenesis in vivo and in vitro.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Anticarcinogenic Agents; Arsenites; Cacodylic Acid; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Transformation, Neoplastic; Chelating Agents; DNA Damage; Humans; Male; Matrix Metalloproteinase 9; Nitrosative Stress; Rats, Sprague-Dawley; Sodium Compounds; Succimer; Survivin; Urinary Bladder Neoplasms | 2020 |
Therapeutic profile of T11TS vs. T11TS+MiADMSA: a hunt for a more effective therapeutic regimen for arsenic exposure.
Topics: Animals; Apoptosis; Arsenic; Arsenic Poisoning; CD2 Antigens; Cell Transformation, Neoplastic; Chelating Agents; Chelation Therapy; Cytokines; Drug Therapy, Combination; Environmental Exposure; Lymphocytes; Mice; Oxidative Stress; Succimer | 2012 |